US · Healthcare · Biotechnology
EPS came in at -0.12 against a street estimate of -0.16 — a beat of 25.0%.
Analysts rate Aclaris Therapeutics Inc a strong buy (11 buy, 1 hold, 0 sell out of 12) with an average price target of $10.36.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 8.64% |
| BML Capital Management LLC | 8.14% |
| BlackRock Inc | 6.82% |
| Deep Track Capital, LP | 6.35% |
| Vivo Capital, LLC | 4.55% |
| Vanguard Capital Management, LLC | 3.95% |
| Frazier Life Sciences Management, L.P. | 3.35% |
| Rock Springs Capital Management LP | 2.94% |
| Document | Date |
|---|---|
| Material agreement · Q4 2026 HEADLINE NUMBERS • Aclaris Therapeutics entered into an agreement on October 27, 2026, to sell 7,785,714 common shares and pre-funded warrants to pur | 2026-10-27 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Aclaris reported Phase 1b proof-of-concept results for ATI-052, an investigational bispecific antibody targeting TSLP and IL-4Rα, | 2026-10-27 |
| Quarterly report · Q2 2026 ACLARIS THERAPEUTICS, INC. – FORM 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash & Marketable Securities: $170.6 million | 2026-08-06 |
| Material agreement · Q3 2026 ACLARIS THERAPEUTICS, INC. – FORM 8-K SUMMARY August 6, 2026 --- HEADLINE NUMBERS • Company entered into a Second Amended and Restated Sales Agreem | 2026-08-06 |
| Results announced · Q3 2026 ACLARIS THERAPEUTICS – Q2 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash Position: $170.6 million in cash, cash equivalents and marketabl | 2026-08-06 |
| Shareholder vote results · Q2 2026 ACLARIS THERAPEUTICS, INC. — FORM 8-K SUMMARY HEADLINE NUMBERS • Annual meeting held June 4, 2026 • 139,663,680 shares outstanding as of record date | 2026-06-04 |
| Quarterly report · Q1 2026 ACLARIS THERAPEUTICS, INC. — Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and cash equivalents: $28.66 million at March 31, 2026 (vs. $19.96 million | 2026-05-07 |
| Results announced · Q2 2026 ACLARIS THERAPEUTICS - Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Net loss: $19.8 million (Q1 2026) vs. $15.1 million (Q1 2025) • Total revenue: $ | 2026-05-07 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aclaris Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.